Ionis Pharmaceuticals IONS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$92.53M+37.0% | -$229.39M-120% | -$128.61M+8.5% | $123.55M+286% | -$146.94M-2.9% | ||
| $3.3M+48.2% | $3.26M+45.5% | $2.26M-4.5% | $2.27M-8.1% | $2.23M-12.5% | ||
| $43.28M+45.6% | $43.32M+19.8% | $31.15M-2.6% | $29.69M-3.4% | $29.72M-5.2% | ||
| $218K+87.9% | -$308K-109% | $213K+106% | -$20K-131% | $116K+52.6% | ||
| $2.35M+43.1% | $1.97M+17.6% | $1.65M-1.5% | $1.65M-1.5% | $1.64M-1.5% | ||
| -$338K+66.5% | $0-100% | $2.14M— | $13.48M+1,591% | -$1.01M-102% | ||
| -$3.1M+88.1% | —— | -$8.81M-309% | —— | -$25.97M-44,114% | ||
| $7.39M-40.2% | —— | $100.95M— | $10.17M-50.2% | $12.37M+212% | ||
| $21M+6,207% | —— | $84.15M— | $3.2M— | $333K+101% | ||
| $7.63M+115% | $67.58M— | -$27.97M-200% | $12.87M— | -$52.48M+43.3% | ||
| -$20.82M-51.8% | -$19.13M-33.8% | -$16.11M+51.1% | -$20.77M+66.9% | -$13.72M+70.7% | ||
| $161K+75.0% | $2.61M+37,414% | $20K+108% | $0— | $92K+101% | ||
| $40K-34.4% | $4.63M+129% | -$3.94M-735% | $236K-7.8% | $61K-54.1% | ||
| $22.58M+1,144% | $788K+131% | $29.91M+3,303% | -$18.31M-418% | -$2.16M— | ||
| $3.49M+34.7% | $3.44M+34.1% | $1.63M-35.3% | $2.59M+3.9% | $2.59M+4.9% | ||
| -$792.82M-426% | -$137.71M-18.6% | -$131.44M-14.3% | $151.34M+226% | -$150.78M-0.6% | ||
| $21.76M+73.0% | $21.29M-16.5% | $5.27M-41.8% | $12.31M+97.4% | $12.58M+180% | ||
| $192.76M-38.0% | $791.97M+137% | $323.94M-54.7% | $491.59M+72.6% | $311.07M-40.1% | ||
| $752.82M+52.2% | $395.12M-8.1% | $422.21M+13.8% | $385.79M+5.0% | $494.76M-17.7% | ||
| $1.49M+128% | $1.37M-46.4% | $1.66M— | $1.96M-86.0% | $651K-47.4% | ||
| —— | —— | $19.6M— | —— | —— | ||
| —— | $228.9M+1.6% | $228.9M+1.6% | $228.9M+1.6% | $228.9M+1.6% | ||
| $536.82M+215% | -$419.51M— | $91.34M+127% | -$120.07M-292% | $170.46M+124% | ||
| $57.3M+2,457% | $0-100% | -$3.53M-101% | $1.29M-50.4% | $2.24M-90.5% | ||
| $57.26M+2,504% | $591.18M— | $81.22M-83.6% | $1.25M-51.2% | $2.2M-90.7% | ||
| -$138K-159% | —— | —— | $595K+2,687% | $232K+304% | ||
| -$198.88M-999% | $33.92M+137% | $41.04M— | $33.11M+160% | $22.12M+144% | ||
| $90K-2.2% | $5.38M+4.4% | $185K+27.6% | $5.12M-6.4% | $92K-3.2% | ||
| -$8K+98.0% | —— | -$278K-447% | —— | -$400K-3,177% | ||
| $6.19M-12.9% | $5.67M-40.0% | $5.09M-44.4% | $5.87M-40.6% | $7.11M-23.2% | ||
| $43.28M+45.6% | $43.32M+19.8% | $31.15M-2.6% | $29.69M-3.4% | $29.72M-5.2% | ||
| $2.35M+43.1% | $1.97M+17.6% | $1.65M-1.5% | $1.65M-1.5% | $1.64M-1.5% | ||
| $661K+13.6% | $638K+39.0% | $621K+0.6% | $598K-3.7% | $582K-8.9% | ||
| $3.3M+48.2% | $3.26M+45.5% | $2.26M-4.5% | $2.27M-8.1% | $2.23M-12.5% | ||
| $22.58M+1,144% | $788K+131% | $29.91M+3,303% | -$18.31M-418% | -$2.16M-193% | ||
| —— | —— | —— | —— | —— | ||
| $7.63M+115% | —— | -$27.97M-200% | —— | -$52.48M+43.3% | ||
| —— | $669.75K+227% | $669.75K+227% | $669.75K+227% | $669.75K+227% | ||
| $21M+6,207% | —— | $84.15M— | $3.2M— | $333K+101% | ||
| -$80.19M-86.3% | $59.22M+104% | —— | —— | -$43.04M+6.8% | ||
| $7.39M-40.2% | —— | $100.95M— | $10.17M-50.2% | $12.37M+212% | ||
| —— | $4.09M— | $4.09M— | $4.09M— | $4.09M— | ||
| $3.49M+34.7% | $3.44M+34.1% | $1.63M-35.3% | $2.59M+3.9% | $2.59M+4.9% | ||
| $22.58M+1,321% | $0+100% | $29.91M— | -$18.62M-427% | -$1.85M-179% | ||
| $1.49M+128% | $1.37M-46.4% | $1.66M— | $1.96M-86.0% | $651K-47.4% | ||
| $752.82M+52.2% | $395.12M-8.1% | $422.21M+13.8% | $385.79M+5.0% | $494.76M-17.7% | ||
| —— | —— | $19.6M— | —— | —— | ||
| $57.3M+2,457% | $107.82M+26,720% | $81.26M+1,061% | $1.29M-50.4% | $2.24M-90.5% | ||
| $44K+4.8% | $52K+26.8% | $41K-14.6% | $40K+2.6% | $42K+7.7% | ||
| —— | $19.6M-52.8% | $19.6M-52.8% | $19.6M-52.8% | $19.6M-52.8% | ||
| $2.98M+104% | $7.96M+108% | $2.34M+118% | $4.15M-0.3% | $1.46M-32.0% | ||
| $363.52M+30.5% | $417.79M+23.8% | $316.9M+12.2% | $312.23M+7.2% | $278.47M+3.5% | ||
| —— | $446.5K+129% | $446.5K+129% | $446.5K+129% | $446.5K+129% | ||
| —— | $645K+404% | $645K+404% | $645K+404% | $645K+404% | ||
| —— | $2.65M+23.3% | $2.65M+23.3% | $2.65M+23.3% | $2.65M+23.3% | ||
| —— | 21%0.0% | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -5.1%-2.8% | —— | —— | —— | ||
| —— | -0.1%-2.7% | —— | —— | —— | ||
| —— | -4.7%— | —— | —— | —— | ||
| —— | -$95.3M+17.3% | -$95.3M+17.3% | -$95.3M+17.3% | -$95.3M+17.3% | ||
| —— | $394.75K+145% | $394.75K+145% | $394.75K+145% | $394.75K+145% | ||
| —— | —— | —— | —— | —— | ||
| $5.16M+25.6% | $4.83M+15.2% | $4.21M+1.2% | $4.11M-8.4% | $4.11M-1.1% | ||
| 1+300% | 0.3— | 0.3— | 0.3— | 0.3— | ||
| -$138K-159% | $0+100% | -$82K-123% | $595K+2,579% | $232K+305% | ||
| —— | $203.33M-10.3% | —— | —— | —— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $1.79M+96.2% | $1.79M+96.2% | $1.79M+96.2% | $1.79M+96.2% | ||
| —— | $34.25K-98.2% | $34.25K-98.2% | $34.25K-98.2% | $34.25K-98.2% | ||
| —— | $11.5K— | $11.5K— | $11.5K— | $11.5K— | ||
| —— | -$162K— | -$162K— | -$162K— | -$162K— | ||
| -$8K+98.0% | —— | -$278K-447% | —— | -$400K-3,177% | ||
| -$814.58M-399% | -$159M-12.3% | -$136.71M-10.2% | —— | -$163.35M-5.8% | ||
| -$814.58M-399% | -$159M-12.3% | -$136.71M-10.2% | —— | -$163.35M-5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ionis Pharmaceuticals generate?
- Ionis Pharmaceuticals (IONS) generated -$910.6M in operating cash flow over the trailing twelve months.
- What is Ionis Pharmaceuticals's free cash flow?
- After $60.6M of capital expenditures, Ionis Pharmaceuticals's free cash flow was -$1.3B over the trailing twelve months, down 133.2% year over year.
- Where does Ionis Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
